Overview

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Pembrolizumab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with piamprilumab in patients with relapsed and refractory lymphoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.